header logo image


Page 1,503«..1020..1,5021,5031,5041,505..1,5101,520..»

Test-tube burger 'petri dish' of the day

February 24th, 2012 8:00 pm

Heston Blumenthal is set to serve up a 207,000 'test-tube' burger later this year.

The tasty meal will be the first beef patty ever created in the laboratory thanks to the efforts of Dutch stem cell scientist Dr Mark Post, from the University of Maastricht.

Speaking at the annual meeting of the American Association for the Advancement of Science (AAAS) in Vancouver, Canada, Dr Post said: 'In October we're going to provide a proof-of-concept showing that with in-vitro methods, out of stem cells we can make a product that looks like and feels and hopefully tastes like meat.

'That first hamburger is going to cost 250,000 euros.'

After experiments which progressed from mouse meat to pork, it will make a grand public entrance in October.

The current plan is for Blumenthal to cook it for a mystery guest, to be chosen by the research project's anonymous funder.

The minced meat will have been grown from bovine muscle and fat stem cells cultured in Dr Post's laboratory.

Currently Dr Post is still working with unappetising half-millimetre thick strips of lab-grown meat that are pinky-yellow in colour.

But he is confident that over the course of this year he will produce a burger virtually indistinguishable from one bought in the high street.

The research has a serious aim - to address the problem of unsustainable livestock farming.

'These animals are very inefficient in the way they convert vegetable matter to animal protein,' he said.

Test Tube Burger Is 'Petri Dish' Of The Day

1 Comments

The research aims to address the problem of unsustainable livestock farming

3:57am UK, Monday February 20, 2012

Heston Blumenthal is set to serve up a 207,000 'test-tube' burger later this year.

The tasty meal will be the first beef patty ever created in the laboratory thanks to the efforts of Dutch stem cell scientist Dr Mark Post, from the University of Maastricht.

Speaking at the annual meeting of the American Association for the Advancement of Science (AAAS) in Vancouver, Canada, Dr Post said: 'In October we're going to provide a proof-of-concept showing that with in-vitro methods, out of stem cells we can make a product that looks like and feels and hopefully tastes like meat.

'That first hamburger is going to cost 250,000 euros.'

After experiments which progressed from mouse meat to pork, it will make a grand public entrance in October.

The current plan is for Blumenthal to cook it for a mystery guest, to be chosen by the research project's anonymous funder.

The minced meat will have been grown from bovine muscle and fat stem cells cultured in Dr Post's laboratory.

Currently Dr Post is still working with unappetising half-millimetre thick strips of lab-grown meat that are pinky-yellow in colour.

But he is confident that over the course of this year he will produce a burger virtually indistinguishable from one bought in the high street.

The research has a serious aim - to address the problem of unsustainable livestock farming.

'These animals are very inefficient in the way they convert vegetable matter to animal protein,' he said.

'Cows and pigs have an efficiency rate of about 15%, which is pretty inefficient. Chickens are more efficient and fish even more.

'Meat demand is going to double in the next 40 years. Right now we are using 70% of all our agricultural capacity to grow meat through livestock.

'You can easily calculate that we need alternatives. If you don't do anything meat will become a luxury food and be very, very expensive.'

In time, he expected the cost of test-tube meat to be brought down to affordable levels. It may then present consumers with the same kind of choice they currently have between buying battery farm or free range eggs.

The process of making test tube meat involves first obtaining the stem cells and allowing them to proliferate around 30-fold. Every muscle cell is accompanied by four or five stem cells.

The stem cells are grown in a culture medium containing all the nutrients and vitamin 'food' they need.

To construct three dimensional tissue, the cells are mixed with a collagen gel in a culture dish containing velcro 'anchor points'.

Between the anchor points, they self-organise into fully-fledged chunks of muscle. An important step is to make them contract using electrical stimulation.

Finally the beef strips are harvested, minced up, and moulded into a patty. To make the burger more realistic, the muscle meat is mixed with fat grown the same way from a different kind of stem cell.

Three thousand pieces of muscle are combined with around 200 pieces of fat.

Dr Post refuses to reveal the identity of the private individual financing the research, who wants to remain anonymous.

But he said he was a well known figure with 'deep pockets'.

Follow this link:
Test-tube burger 'petri dish' of the day

Read More...

euronews science – In Vitro meat – Video

February 24th, 2012 12:54 pm

23-02-2012 14:54 http://www.euronews.net Dutch scientist Mark Post hopes that he will be able to produce the world's first test-tube burger later this year. He says it will look, and taste identical to a regular quarter-pounder. In the laboratory, he has already grown small strips of beef from bovine stem cells, and is now looking at ways to increase production. It is white because there are no blood cells. But researchers hope that once cooked, these cells will look and taste the same as conventionally produced meat.

See original here:
euronews science - In Vitro meat - Video

Read More...

Stem cell therapy for corneal scarring: the impact of donations – Video

February 24th, 2012 12:51 pm

17-02-2012 10:13 The Louis J. Fox Center for Vision Restoration received several major donations from the Western Medical Eye Bank Foundation. These donations are used to further the research on stem cell therapy for corneal scarring. Watch Mr. Wisnoski and Dr. Funderburgh discuss why this research is important.

More here:
Stem cell therapy for corneal scarring: the impact of donations - Video

Read More...

BrainStorm Featured on CNBC

February 24th, 2012 12:50 pm

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI.OB - News), a developer of innovative stem cell technologies for neurodegenerative disorders, announced that NurOwn™, its autologous stem cell therapy for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's Disease, was profiled yesterday on CNBC. In the Feature Story about the impact of Iran's nuclear threat, Israeli business and scientific leaders were interviewed about Israel's thriving economy and cutting edge technologies. Among those leaders that met with CNBC were Brainstorm’s President Mr. Chaim Lebovits and Prof. Dimitrios Karussis, Principal Investigator of Brainstorm's Phase I/II clinical trial currently underway at the Hadassah Medical Center in Jerusalem.

Brainstorm recently announced positive initial results from the clinical trial, resulting in approval from Hadassah's Helsinki committee to proceed with the trial. Accordingly, additional patients have been enrolled in the study, and Brainstorm will announce additional results in the coming months.

To see the video online, follow the link at: http://video.cnbc.com/gallery/?video=3000074883

To read the Feature Story online, follow the link at: http://www.cnbc.com/id/46484576

Safe Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. The Company does not undertake any obligation to update forward-looking statements made by us.

Link:
BrainStorm Featured on CNBC

Read More...

U of M researchers aim to restore heart muscle using stem cells

February 24th, 2012 4:54 am

MINNEAPOLIS - A first-of-its-kind study is just getting underway at University of Minnesota Physicians Heart at Fairview, in Minneapolis. The FDA-approved trial is designed to test the impact of stem cells on restoring the heart's muscle function in patients suffering from advanced heart failure. The results of the trial could impact the future of health care in the area of heart disease, and may one day save lives.

Lee Magnuson, 58, of Spring Brook, WI, became one of the first patients to enroll in the study.

"To me it was a no brainer, I had to contribute," said Magnuson.

Magnuson suffered a heart attack on October 5, 2010. He spent about a year being treated with medication and undergoing cardiac rehabilitation in an attempt to strengthen his heart muscle.

But, by August of 2011, he said, his doctor could tell things were not going well. That is when his doctor recommended implanting a left ventricular assist device (LVAD). The device helps pump blood from the lower left chamber of the heart to the rest of the body. His doctor also told him about the U of M study.

"This trial is designed for heart failure patients in the end stage of heart failure, with no options for treatment," explained Ganesh Raveendran, M.D., who is the principal investigator of the clinical trial. "The question this trial is designed to answer is whether or not patients on a left ventricular assist device with the stem cell component do better than patients with only the device, which right now is the standard care for patients experiencing advanced heart failure."

The trial is currently enrolling qualified patients. All patients involved in the study will undergo a marrow harvest in which stem cells will be taken from the marrow of their own hip bone. Then, during implantation of the LVAD, two thirds of the patients enrolled in the study will receive an injection of their own stem cells. A third of the patients will be randomly assigned to the control group, and will receive only an LVAD and an injection of saline.

The trial is double-blind, meaning U of M researchers will not know which patients have received stem cells and which did not until the trial concludes.

So far, three patients have enrolled. Researchers hope to eventually recruit 24 people from around the region. The study will last approximately two years.

In November, Magnuson became the first of the patients to have an LVAD implanted and receive an injection.

Throughout the trial, Magnuson and the other patients will undergo a series of tests in which doctors slowly decrease the effort of the LVAD and place more pressure back on the heart's own pumping function. The purpose of the tests is to assess the impact of the stem cells on restoring the functionality of heart muscle. Researchers want to know whether there is any improvement in the size of the heart and the pressure inside the heart chambers. The tests include echocardiograms, PET scans, walking assessments, blood pressure measurements and quality-of-life questioning.

Researchers will eventually compare the results of those tests to see if there was a difference between the two groups of patients.

"The hope is that this group of patients suffering from severe heart failure eventually should be able to get some cells and improve the heart function," said Dr. Raveendran.

That answer will come once the patients either undergo a transplant or they die. Only then will doctors be able to study the hearts to learn the true impact of the stem cells.

Last month, Magnuson was put on a waiting list for a heart transplant.

"So it's a matter of waiting now, it's a matter of time," explained Magnuson.

He remains optimistic about the future, but says his heart issues also have taught him to be a realist.

"My quality of life is, before it was work, work, work, and it's going to not be so much work anymore and we're going to enjoy things," reflected Magnuson. "You all of a sudden realize that you're not going to live forever."

To learn more about the study:
Call the U of M Physicians Heart at Fairview - 612-625-5949
Email - stemcells@umnheart.com
Webpage - http://www.med.umn.edu/lcru/

You Might Be Interested In

Read this article:
U of M researchers aim to restore heart muscle using stem cells

Read More...

Lineage trees reveal cells' histories

February 24th, 2012 4:54 am

The method, developed over several years in the lab of Prof. Ehud Shapiro of the Institute's Biological Chemistry, and Computer Science and Applied Mathematics Departments, uses mutations in specific genetic markers to determine which cells are most closely related and how far back they share a common parent cell, to create a sort of family tree for cells. Shapiro and members of his lab, including Drs. Shalev Itzkovitz and Rivka Adar, together with Prof. Nava Dekel and research student Yitzhak Reizel of the Biological Regulation Department, used their method to see if ova could be descended from bone-marrow stem cells. Their findings indicated that any relationship between the two types was too distant for one to be an ancestor of the other.

These scientists also found, surprisingly, that the ova of older mice had undergone more cell divisions than those of younger mice. This could be the result of replenishment during adulthood, but an alternate theory holds that all eggs are created before birth, and those that undergo fewer divisions are simply selected earlier on for ovulation. Further experimentation, says Shapiro, will resolve the issue.

Cell lineage trees are similar to modern evolutionary and taxonomic trees based on genome comparisons between organisms. Shapiro and his team used mutations in cells that are passed on to daughter cells over an organism's lifetime (though not on to the next generation). By comparing a number of genetic sequences called microsatellites – areas where mutations occur like clockwork – they can place cells on trees to reveal their developmental history.

A number of papers published by Shapiro, his team and collaborators in recent months have demonstrated the power and versatility of this method. One study, for instance, lent support to the notion that the adult stem cells residing in tiny crypts in the lining of the colon do not harbor, as thought, "immortal DNA strands." Immortal strands may be retained by dividing stem cells if they always relegate the newly-synthesized DNA to the differentiating daughter cell and keep the original stand in the one that remains a stem cell.

A second study addressed an open question about developing muscle cells. Here they found that two kinds of progenitor cell - myogenic cells, which eventually give rise to muscle fiber, and non-myogenic cells – found within the same muscle are more closely related than similar cells in different muscles.

One immediate advantage of the cell lineage analysis method developed by Shapiro's team is that it is non-invasive and retrospective, and as such can be applied to the study of human cell lineages. Most other studies of development rely on genetically engineered lab animals in which the stem cells are tagged with fluorescent markers. In addition to providing a powerful new research method that does not rely on such markers, Shapiro believes that it could one day be adapted as a diagnostic tool that might, for instance, reveal the history of an individual's cancer and help doctors determine the best course of treatment.

Provided by Weizmann Institute of Science (news : web)

Here is the original post:
Lineage trees reveal cells' histories

Read More...

ISSCR Honors Stem Cell Research Pioneer with Prestigious McEwen Award for Innovation

February 24th, 2012 4:54 am

Newswise — The International Society for Stem Cell Research (ISSCR) is pleased to announce the winner of the 2012 McEwen Award for Innovation, a coveted prize in the field of stem cell research and regenerative medicine. The 2012 recipient is Rudolf Jaenisch, MD, Founding Member of the Whitehead Institute for Biomedical Research and Professor of Biology at the Massachusetts Institute of Technology in recognition of his pioneering discoveries in the areas of genetic and epigenetic control of development in mice that directly impact the future potential of embryonic stem cells and induced pluripotent stem cells for therapeutic utility.

The McEwen Award for Innovation is supported by the McEwen Centre for Regenerative Medicine in Toronto, Ontario, Canada. The $100,000 award honors original thinking and groundbreaking research pertaining to stem cells or regenerative medicine that opens new avenues of exploration towards the understanding or treatment of human disease or affliction.

“Rudolf Jaenisch has consistently contributed new and groundbreaking discoveries to stem cell biology and regenerative medicines that have changed the way stem cell research is conducted, said Fred H. Gage, PhD, ISSCR President. “Importantly, Rudolf not only has an uncanny sense of the next big question, but also conducts his experiments with such thoughtful and critical experimental design that his results have an immediate impact. This critical attention to detail and experimental design has greatly benefited the many gifted students that have passed through his lab and now populate many of the major stem cell centers throughout the world. Rudolf is very deserving of this award.”

Winner of the inaugural McEwen Award for Innovation in 2011, Shinya Yamanaka, MD, PhD, ISSCR President-Elect agrees. “Dr. Rudolf Jaenisch has always been on the cutting-edge of our field and his research has been a source of inspiration not only for myself, but has influenced the careers of some of our most esteemed colleagues.”

Dr. Jaenisch will be presented with the award at the ISSCR 10th Annual Meeting, in Yokohama, Japan, on Wednesday, June 13, 2012.
***
The International Society for Stem Cell Research is an independent, nonprofit membership organization established to promote and foster the exchange and dissemination of information and ideas relating to stem cells, to encourage the general field of research involving stem cells and to promote professional and public education in all areas of stem cell research and application.

Comment/Share

Read the original here:
ISSCR Honors Stem Cell Research Pioneer with Prestigious McEwen Award for Innovation

Read More...

Where Science Meets Faith: Anticipating the Future – Video

February 24th, 2012 4:52 am

16-11-2011 11:19 For more on Jesuits and their mission, visit: http://www.nationaljesuitnews.com Jesuit Father Kevin FitzGerald is a Research Associate Professor in the Division of Biochemistry and Pharmacology of the Department of Oncology and the Dr. David P. Lauler Chair for Catholic Health Care Ethics. He is also a member of the Center for Clinical Bioethics, the Advisory Board for the Center for Infectious Disease (CID), and the Angiogenesis, Invasion, Metastasis Program at the Lombardi Comprehensive Cancer Center. His research interests have included the investigation of abnormal gene regulation in cancer and ethical issues in human genetics, including the ethical and social ramifications of molecular genetics research. He is an expert on ethical issues in personalized medicine, pharmacogenomics, human cloning research, stem cell research, and genetic testing.

Link:
Where Science Meets Faith: Anticipating the Future - Video

Read More...

Buzz:Test tube beef – Video

February 23rd, 2012 6:50 pm

21-02-2012 05:39 (WTNH)-- Would you be willing to eat a burger that was grown in a test tube? Researchers say they have come up with a way to grow meat in a lab using animal stem cells.

View post:
Buzz:Test tube beef - Video

Read More...

Is 'in vitro meat' moving closer to the menu?

February 23rd, 2012 6:50 pm

VANCOUVER, British Columbia -- In a laboratory in the Netherlands, stem cells from cows are being grown into what researcher Mark J. Post says will be the first so-called "test-tube burger" -- comprising the tiny pieces of tissue-engineered, or "in vitro," meat -- that he and his colleagues aim to cook and taste as early as this October.

By this summer, California researcher Patrick O. Brown says, a company he's helped start will bring to market a revolutionary new plant-based substitute for a meat or dairy food -- he's not yet sharing specifics -- that "can't be distinguished from the animal product it replaces, even by hard-core foodies."

The scientists are on the leading edge of a movement to dramatically change how the world grows and consumes meat, something they say must happen, one way or another.

"Animal farming is by far the biggest ongoing global environmental catastrophe," Mr. Brown said Sunday at a news briefing for journalists from around the world at the annual meeting of the American Association for the Advancement of Science, attended by some 5,000 delegates and 700 media people in Vancouver.

He and Mr. Post were part of a panel of four experts who later that day presented a symposium titled, "Meat without Animals: Test-tube Burgers and More." It was provocative enough that the Times of London broke a news embargo to publish something on it that morning, and bits of the story have been broadcast this week as far and wide as the local TV news in Pittsburgh.

The issue certainly is food for thought.

Mr. Brown, a biochemist at the Stanford University School of Medicine, wants to see a world without animal farming, because "in every conceivable way, it's inefficient and destructive."

Inefficient, in that it takes many pounds of grains, and many, many gallons of water, to make a typical quarter-pounder. Destructive, he said, citing sobering United Nations statistics, that show animal farming takes up about 30 percent of the Earth's land, accounts for more than 18 percent of greenhouse gas emissions, is the largest source of water pollution and the biggest threat to biodiversity.

Meanwhile, the world's appetite for meat is expected to double by 2050.

Mr. Brown called animal agriculture, mostly unchanged for centuries, as "a sitting duck for a disruptive technology."

That's why, with backing from a Silicone Valley venture capital firm, he's launched two startups to create and market alternative foods that, like him, are vegetarian.

Of course, the market already has plenty of meat substitutes and non-dairy "cheeses," but he says they're not very good and they're expensive, and they're marketed to people who've already chosen to be vegetarian or vegan for health or ethical reasons, not to the mainstream.

The products he plans will compete head-on with animal products by being "high-value, protein-rich, nutrient-dense human foods that appeal to consumers" -- stand-ins for everything from bacon to cheddar.

Professor Post of Maastricht University said that he hopes Mr. Brown and others are able to fix the problems of animal agriculture with plants. But because he believes many people want real meat, his research is about producing that in a more efficient, less environmentally degrading way.

Cows are only about 15 percent efficient at making meat from grains and other foods, he said. Making beef under more controlled conditions could feed a lot more people while using fewer resources, saving the grains for human consumption as food as well as biofuel. (Their aim is to grow meat with vegetable-based nutrients, perhaps involving algae.)

With backing of $330,000 from a "reputable," non-food-industry funder he's not yet identifying, his team is working to grow enough muscle cells to show that "cultured meat" is possible.

Already, they've grown bovine stem cells into tiny strips about an inch long and 2/100ths of an inch thick.

They'll need thousands of these to make a burger (the golf-ball-sized goal sounds more like a slider, and an expensive one at that). But that's just one of many challenges.

Growing stem cells happens in labs all over the world, including Pittsburgh, where some researchers envision being able to make replacement organs for humans.

Bits for ground beef, the most popular meat in the U.S., look to be relatively easy. (Mr. Post got laughs when recounting how they started with pig cells, planning to make sausage, which can be "hardly recognizable as a meat product" anyway).

But muscle cells on an animal grow because of conditions that scientists have to figure out how to create in the petri dish. Mr. Post described using electric current to "exercise" the cow muscle cells, and treatments ranging from administering caffeine to withholding light to get them to make more myoglobin, which gives meat its red color.

"Right now, it's sort of a pinkish-yellowish," he told journalists. "The color is an interesting issue."

But, as he said later, it's also a scientifically controllable one. His part of the talk touched on possibilities including lowering the saturated fat and cholesterol of various meats, even creating custom combinations of meats.

His Powerpoint presentation illustrated the ultimate goal -- making "big slabs of meat" -- which were fancifully depicted as octagonal steaks, on round ceramic "bones."

Even if he does taste that burger this fall, cultured filet mignons are a long ways off. They will be expensive, as will all the research it'll take.

"But what's the cost of traditional meat production?" asked Nicholas Genovese, a visiting scholar at the University of Missouri-Columbia who organized the symposium. He includes in that the costs of dealing with outbreaks of food-borne illness and other human health woes associated with animal foods.

One of the issues he stresses is the ethical one of millions of animals being killed. His research, in fact, is funded by a grant from the People for the Ethical Treatment of Animals, which in 2008 offered a $1 million reward for the first researchers to make in vitro chicken meat, indistinguishable from the "real" deal, and sell it to the public by June 30, 2012.

That offer stands and might be extended at a PETA meeting in Los Angeles in April, PETA President Ingrid Newkirk said in a phone interview from Washington, D.C., last week. "Originally, we thought we'd never have to pay out," she said. "Nobody had heard of [in vitro meat]. We wanted to boot it into the public consciousness."

Now, she says, "We're feeling very good" about the research progress that's been made. "If this allows them to get rid of cruelty to animals, fabulous."

She's well aware that the idea of in vitro meat can stir strong reactions from everyone from Midwest farmers to home cooks, but says, "Everybody fears change," and points out that many foods such as soy milk were once little known.

The AAAS panelists included KeShun Liu, a U.S. Department of Agriculture researcher who talked about the next generation of extruded meat "analogs" that mimic the fibers of real chicken and turkey. (He said to look for products soon from Maryland's Savage River Farms).

The panelists agreed they're not advocating for legislation or subsidies; they're just working for alternatives for consumers.

Some acceptance of these new alternatives may be a matter of language. At the AAAS meeting, Mr. Genovese stressed, "In vitro meat will never be produced in the 'lab.' " As beer is made in a brewery, he has proposed calling meat production facilities of the future "carneries."

Bob Batz Jr.: bbatz@post-gazette.com or 412-263-1930.

First published on February 23, 2012 at 12:00 am

See the original post here:
Is 'in vitro meat' moving closer to the menu?

Read More...

Monkeys' Parkinson's woes eased via stem cells

February 23rd, 2012 6:50 pm

Thursday, Feb. 23, 2012

KYOTO — Researchers have succeeded in improving the treatment of Parkinson's disease by using human embryonic stem cells to create nerve cells that produce dopamine and then transplanting the cells into monkeys' brains.

Four monkeys with Parkinson's disease — and previously unable to walk due to their symptoms — improved substantially after the human nerve cells were transplanted into their brains, reducing the shaking in their limbs and leading to some regaining the ability to walk, the research team, including Kyoto University professor Jun Takahashi, said Tuesday.

It is the first time pluripotent human embryonic stem cells have been successfully transplanted to improve symptoms of Parkinson's disease in monkeys, according to the team.

Parkinson's disease is linked to drops in the production of dopamine — a neurotransmitter in the brain. While there are drugs to treat the progressive neurological illness, there is currently no treatment to stop dopamine levels from falling.

In the study, the researchers transplanted nerve cells derived from the human stem cells into the four monkeys' brains. About three months later, all of them began to show improvements in their symptoms and tests conducted a year after the operation confirmed the nerve cells had been successfully grafted in their brains.

The finding holds much promise for the future treatment of Parkinson's disease in humans using regenerative medicine, but the researchers cautioned that a lot more work lies ahead as the study also showed that transplanted nerve cells that were not appropriately matured led to the development of tumors, although they were not malignant and could be treated.

See the article here:
Monkeys' Parkinson's woes eased via stem cells

Read More...

Japanese researchers find stem cells reduce monkeys' Parkinson's symptoms

February 23rd, 2012 6:50 pm

Japanese researchers have been able to improve the symptoms of Parkinson's disease in monkeys by transplanting nerve cells derived from embryonic stem cells into their brains, the team has announced.

The finding is the world's first reported success of its kind with a primate, according to the research team led by associate professor Jun Takahashi of Kyoto University's Institute for Frontier Medical Sciences. It has been released in the online edition of US journal Stem Cells.

After the transplant, the monkeys, which had been almost unable to move, showed improvements in their symptoms to the point where they became able to walk on their own, the team said.

Parkinson's disease is a neurological illness believed to be caused by a deficit of the neurotransmitter dopamine in the brain.

Embryonic stem cells, which have the potential to become almost any type of tissue, are harvested from inside a blastocyst, which develops from a mammalian egg cell about a week after it is fertilised.

Takahashi's research team used the embryonic stem cells to cultivate a cell mass in which 35 per cent of the cells were dopamine-producing neurons.

These neurons then were transplanted into the four crab-eating monkeys, whose conditions were observed over a one-year period.

According to the study, the monkeys exhibited reduced shaking of their limbs half a year later. They had remained nearly motionless inside their cages all day long before the transplant, but the improvement of their symptoms eventually enabled them to occasionally walk around the cages.

The research team confirmed that normal nerve cells had been created in their brains.

The finding could mark a major breakthrough for applying embryonic stem cells in clinical settings, experts said. The Health, Labour and Welfare Ministry has been encouraging researchers to study the clinical applications of not only stem cells, but also induced pluripotent stem cells, which also can grow into many kinds of human cells.

Takahashi's team has already performed experiments to transplant iPS cells into monkeys' brains.

"We'll make further efforts to enhance the safety of these cell transplants," Takahashi said. "And we hope to start clinical application studies as early as three years from now."

Go here to read the rest:
Japanese researchers find stem cells reduce monkeys' Parkinson's symptoms

Read More...

Bone Marrow Prolotherapy at Caring Medical – Dr. Ross Hauser – Video

February 23rd, 2012 6:49 pm

28-12-2010 13:43 Ross Hauser, MD is a full time Prolotherapy physician in Chicago land. He offers comprehensive Prolotherapy, including Bone Marrow Prolotherapy, also known as Stem Cell Prolotherapy. In this video, he discusses the stem cell treatment and how the bone marrow is obtained and administered. If you are interested in Prolotherapy, please visit: http://www.caringmedical.com

Originally posted here:
Bone Marrow Prolotherapy at Caring Medical - Dr. Ross Hauser - Video

Read More...

Global Tissue Engineering Market Review Recently Published at MarketPublishers.com

February 23rd, 2012 6:46 pm

New market research report “Tissue Engineering: The Combination of Cells & Engineering - A Global Market Overview” developed by Industry Experts has been recently published by Market Publishers Ltd. The report reveals that the global market for tissue engineering is projected to touch USD 27 billion by 2018 from an estimated USD 6.6 billion in 2008, witnessing a healthy CAGR of 15%.

London, UK (PRWEB) February 22, 2012

The global market for tissue engineering is projected to touch USD 27 billion by 2018 from an estimated USD 6.6 billion in 2008, witnessing a healthy CAGR of 15%. Factors that are expected to influence this market and its explosive growth include political forces, government funding, clinical trial results, fluctuating industry investment and an increasing awareness among both physicians and the general public of the accessibility of cell therapies for medical applications.

New market research report “Tissue Engineering: The Combination of Cells & Engineering - A Global Market Overview” developed by Industry Experts has been recently published by Market Publishers Ltd.

Report Details:

Title: Tissue Engineering: The Combination of Cells & Engineering - A Global Market Overview

Published: February, 2012

Pages: 153

Price: US$ 3,600

http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/healthcare_equipment_services/tissue_engineering_combination_of_cells_engineering_a_global_market_overview.html

The report provides a thorough examination of the market for tissue engineering globally and across individual regions including the United States, Europe, Asia-Pacific and ROW. The study features statistical data for the market and provides profiles of 60 major tissue engineering market players. Future forecasts are also reviewed in detail.

Report Contents:

1. Introduction

2. Product Outline

2.1 Biomaterials

2.2 Cells

2.3 Biomolecules

2.4 Aspects of Engineering Design

2.5 Biomechanical Design Aspects

2.6 Informatics to Support Tissue Engineering

2.7 Stem Cell Research

2.8 Therapeutic Applications of Tissue Engineering and Regenerative Medicine

2.8.1 Orthopedic Applications

    2.8.1.1 Bone Regeneration Using Orthopedic Tissue Engineering

    2.8.1.2 Articular Cartilage Degeneration and Osteoarthritis, Repair, Regeneration and Transplantation

     2.8.1.2.1 Cartilage Repair

     2.8.1.2.2 Osteochondral Allograft Transplantation

2.8.2 Skin/Integumentary Applications

    2.8.2.1 Burns

    2.8.2.2 Diabetic Ulcers

    2.8.2.3 Venous Ulcers

    2.8.2.4 Plastic and Reconstructive Surgery

2.8.3 Oncology Applications

    2.8.3.1 Cancer

    2.8.3.2 Cancer Biology from Tissue Engineering’s Perspective

    2.8.3.3 Tissue Engineering Technology Platforms’ Translation into Cancer Research

2.8.4 Cardiovascular Applications

    2.8.4.1 Cardiac Tissue Engineering: An Overview

    2.8.4.2 Identification of Basic Cell Responses

     2.8.4.2.1 Materials and Degradation

     2.8.4.2.2 Attachment

     2.8.4.2.3 Stiffness

     2.8.4.2.4 Diffusion and Porosity

     2.8.4.2.5 Forces

    2.8.4.3 3-Dimensional Tissue Engineering

    2.8.4.4 Further 3-D Approaches and Considerations

    2.8.4.5 Cardiovascular Tissue Engineering and Bioreactor Technology

    2.8.4.6 Limiting Cells or Materials

2.8.5 Dental

    2.8.5.1 Dental Tissue Regeneration through Tissue Engineering Strategy

    2.8.5.2 Harvesting Teeth Created by Tissue Engineering

    2.8.5.3 Research Goals Currently Targeted

    2.8.5.4 Process of Tissue Engineering for Tooth Replacement: What Future Trends Indicate

2.8.6 Neurology Applications

    2.8.6.1 Neural Tissue Engineering or Neuroregeneration

    2.8.6.2 Biomaterial Scaffold Development for Nerve Tissue Engineering: Biomaterial Mediated Neural Regeneration

     2.8.6.2.1 Response to Injury and Repair

     2.8.6.2.2 Neural Cells’ Regeneration Potential

     2.8.6.2.3 Regeneration Promoted through Growth Factor Delivery

     2.8.6.2.4 Biomaterials in Nerve Regeneration

     2.8.6.2.5 Polymeric Scaffolds as Extracellular Matrix Analogues

     2.8.6.2.6 Geometric Indicators: Structure of Scaffolds

     2.8.6.2.7 Nanofiber Properties and Electrospinning Technology

     2.8.6.2.8 Alternate Approaches

     2.8.6.2.9 Electrical Cues

...

More new market research reports by the publisher can be found at Industry Experts page.

###

Tanya Rezler
The Market Publishers, Ltd
+44 208 144 6009
Email Information

Read the original post:
Global Tissue Engineering Market Review Recently Published at MarketPublishers.com

Read More...

GeneCell International’s Director of Research and Laboratory Operations is Invited to Speak at a Local Middle School …

February 23rd, 2012 6:46 pm

Dr. Todd Flower, Director of Research and Laboratory Operations at GeneCell International, has been invited to speak at the Jorge Mas Canosa Middle School on career day to a group of students about the science behind adult stem cells.

Miami, FL. (PRWEB) February 22, 2012

Dr. Todd Flower, Director of Research and Laboratory Operations at GeneCell International, has been invited to speak at the Jorge Mas Canosa Middle School on career day to a group of students about the science behind adult stem cells.

Dr. Todd R. Flower will be set to speak on Friday, March 9, 2012, from 9:40am to 1:30pm, to 4 different groups of 6th, 7th, and 8th grade students. The talk will be centered on the science of adult stem cells, its potential medical uses, as well as the use of liquid nitrogen and cryogenic procedures. “As a scientific institution, we need to educate the public and give back to our community, therefore, I look forward to meeting with this group of young bright individuals who we can hopefully inspire to become scientists”, said Dr. Todd R. Flower.    

Adult stem cells can be found and isolated from several different adult tissue types including but not limited to: bone marrow, umbilical cord blood, dental pulp tissue, adipose (fat) tissue, menstrual blood, synovial fluid etc. The stem cells isolated from these adult tissues have the ability to differentiate (mature into) numerous other cell types giving them the potential to treat a variety of different disease states.

GeneCell International is the only cutting-edge laboratory in Miami that specializes in the collection, transport, processing and cryogenic storage of adult stem cells from various sources including; umbilical cord blood, dental pulp and adipose (fat) tissue that can later be used to treat a variety of diseases. The laboratory is also involved in scientific research and development with a range of stem cells from various adult tissues.

“This opportunity allows us to further educate our community to ensure that everyone is given the best and most current information on preserving stem cells that can potentially save a life of a family member,” added GeneCell’s Operation’s Director, Jose Cirino.

Alongside its commitment to educating the public on the benefits of cord blood, dental pulp and adipose tissue preservation, GeneCell is committed to being on the forefront of stem cell research.

About GeneCell International

GeneCell International, LLC is a trusted provider in the collection, processing and storage of adult stem cells from various sources which have the potential to treat a variety of diseases and disorders. Headquartered in Miami, Florida and with local offices in Central Florida, Colombia, Rhode Island, the Dominican Republic, Panama and Venezuela, GeneCell operates state of the art laboratories and storage facilities for the cord blood of thousands of clients. For more information and to learn more about cord blood banking visit http://www.GeneCell.com

###

Lourdes Balestena, Public Relations
GeneCell International, LLC
305-300-0845
Email Information

Originally posted here:
GeneCell International’s Director of Research and Laboratory Operations is Invited to Speak at a Local Middle School ...

Read More...

MediVet-America Partners With Butler Schein Animal Health to Distribute World's Leading Animal Stem Cell Technology to …

February 23rd, 2012 6:45 pm

Global leader in animal stem cell technology is poised for significant expansion through new partnership with top U.S. companion animal health distribution company.

Las Vegas, Nevada (PRWEB) February 22, 2012

MediVet-America, the global leader in veterinary stem cell technology and regenerative medicine, has entered into a distribution partnership with Butler Schein Animal Health, a division of Henry Schein, the leading companion animal health distribution company in the U.S., to sell and distribute stem cell kits and equipment to veterinarians serving the nation’s fast-growing $50 billion pet industry.

The announcement was made today at the Western Veterinary Conference in Las Vegas by Jeremy Delk, CEO of MediVet-America.

The two companies will partner to sell and distribute MediVet-America’s advanced stem cell technology to more than 26,000 veterinary clinics nationwide. Adult animal stem cell technology uses the body’s own regenerative healing power to help treat dogs, cats, horses and other animals suffering from painful arthritis, hip dysplasia and tendon, ligament and cartilage injuries and other ailments.

The Adipose-Derived Stem Cell Procedure Kit and state of the art equipment, co-developed with Medical Australia, enable veterinarians to remove a small sample of fat, separate the stem cells, then activate and inject them into affected areas.

“We are pleased to be teaming up with Butler Schein, the largest companion animal health distribution company in the nation,” said Delk. “Their strong track record in sales and distribution will further fuel our rapid growth and bring this breakthrough technology to more leading veterinary practices across the country.”

To introduce the distribution partnership, Delk said MediVet-America has developed an exclusive program of product and service offers that will be made available only to Butler Schein customers.

Veterinary practitioners in more than 200 markets throughout 42 states now perform the drug-free procedure entirely in their own clinics more quickly, effectively and economically than earlier generation animal stem cell therapy. MediVet-America’s new treatment, developed in Australia, is available in 26 countries worldwide.

“This exciting partnership will allow even more of our colleagues unparalleled access to MediVet-America’s superior technology, providing the most affordable and efficacious stem cell therapy in the industry,” said Mike Hutchinson, D.V.M., the world’s leading animal stem cell practitioner. Dr. Hutchinson, who has spoken around the world about stem cell therapy, most recently in Tokyo, has performed more than 300 procedures over the last 18 months in his practice near Pittsburgh, PA.

Partnering with the leading animal health manufacturers in the world, Butler Schein maintains an order-fill ratio greater than 98 percent, and is positioned to bring the broadest selection of veterinary products and strategic business solutions to veterinarians, including:

    A comprehensive product offering for companion animal, equine and large animal practices including biologicals, diagnostics, nutritionals, parasiticides and pharmaceuticals

    Technology hardware and software solutions     Capital equipment, supply products and repair services     Practice design and remodeling, client marketing and financial solutions

Stem cells are basic biological cells with the ability to differentiate into specialized tissue cells and regenerate new cells to replace or repair damaged tissue. The stem cells used in veterinary medicine are not embryonic, which have attracted controversy over the years, but are taken from adipose (fat) tissue of the adult animal.

Americans spent an estimated $50.8 billion in 2011 on their companion animals, according to the American Pet Products Association, up from $28.5 billion in 2001. MediVet-America’s stem cell treatment costs about $1,800 for small animals, $2,400 for horses. Stem cells also can be frozen and banked for future use through MediVet Lab Services.

MEDIVET-AMERICA

A research and development company and global leader in veterinary stem cell technology, MediVet-America provides innovative cell applications for the therapeutic care of animals. Headquartered in Nicholasville, Kentucky, MediVet-America develops advanced cellular designed kits and services for the treatment of arthritis and degenerative joint disease. The company also offers MediVet Lab Services in multiple locations around the world that provides technical support for in-house stem cell vets, as well as regional and national Adipose stem cell processing and cryo banking services for pets at a young age or for a maintenance program, autologous conditioned serum processing, and cell counting for in-house stem cell procedures. http://www.MediVet-America.com

BUTLER SCHEIN ANIMAL HEALTH

Butler Schein Animal Health is the leading U.S. companion animal health distribution company. Headquartered in Dublin, Ohio, the company operates through 18 distribution centers and 12 telecenters. Approximately 900 Butler Schein Animal Health team members, including 300 field sales representatives and 200 telesales and customer support representatives, serve animal health customers in all 50 states. http://www.ButlerShein.com

###

Dick Roberts
Roberts Communications
(412) 535-5000
Email Information

More here:
MediVet-America Partners With Butler Schein Animal Health to Distribute World's Leading Animal Stem Cell Technology to ...

Read More...

MediVet-America Partners With Butler Schein Animal Health to Distribute World’s Leading Animal Stem Cell Technology to …

February 23rd, 2012 2:24 am

Global leader in animal stem cell technology is poised for significant expansion through new partnership with top U.S. companion animal health distribution company.

Las Vegas, Nevada (PRWEB) February 22, 2012

MediVet-America, the global leader in veterinary stem cell technology and regenerative medicine, has entered into a distribution partnership with Butler Schein Animal Health, a division of Henry Schein, the leading companion animal health distribution company in the U.S., to sell and distribute stem cell kits and equipment to veterinarians serving the nation’s fast-growing $50 billion pet industry.

The announcement was made today at the Western Veterinary Conference in Las Vegas by Jeremy Delk, CEO of MediVet-America.

The two companies will partner to sell and distribute MediVet-America’s advanced stem cell technology to more than 26,000 veterinary clinics nationwide. Adult animal stem cell technology uses the body’s own regenerative healing power to help treat dogs, cats, horses and other animals suffering from painful arthritis, hip dysplasia and tendon, ligament and cartilage injuries and other ailments.

The Adipose-Derived Stem Cell Procedure Kit and state of the art equipment, co-developed with Medical Australia, enable veterinarians to remove a small sample of fat, separate the stem cells, then activate and inject them into affected areas.

“We are pleased to be teaming up with Butler Schein, the largest companion animal health distribution company in the nation,” said Delk. “Their strong track record in sales and distribution will further fuel our rapid growth and bring this breakthrough technology to more leading veterinary practices across the country.”

To introduce the distribution partnership, Delk said MediVet-America has developed an exclusive program of product and service offers that will be made available only to Butler Schein customers.

Veterinary practitioners in more than 200 markets throughout 42 states now perform the drug-free procedure entirely in their own clinics more quickly, effectively and economically than earlier generation animal stem cell therapy. MediVet-America’s new treatment, developed in Australia, is available in 26 countries worldwide.

“This exciting partnership will allow even more of our colleagues unparalleled access to MediVet-America’s superior technology, providing the most affordable and efficacious stem cell therapy in the industry,” said Mike Hutchinson, D.V.M., the world’s leading animal stem cell practitioner. Dr. Hutchinson, who has spoken around the world about stem cell therapy, most recently in Tokyo, has performed more than 300 procedures over the last 18 months in his practice near Pittsburgh, PA.

Partnering with the leading animal health manufacturers in the world, Butler Schein maintains an order-fill ratio greater than 98 percent, and is positioned to bring the broadest selection of veterinary products and strategic business solutions to veterinarians, including:

    A comprehensive product offering for companion animal, equine and large animal practices including biologicals, diagnostics, nutritionals, parasiticides and pharmaceuticals

    Technology hardware and software solutions     Capital equipment, supply products and repair services     Practice design and remodeling, client marketing and financial solutions

Stem cells are basic biological cells with the ability to differentiate into specialized tissue cells and regenerate new cells to replace or repair damaged tissue. The stem cells used in veterinary medicine are not embryonic, which have attracted controversy over the years, but are taken from adipose (fat) tissue of the adult animal.

Americans spent an estimated $50.8 billion in 2011 on their companion animals, according to the American Pet Products Association, up from $28.5 billion in 2001. MediVet-America’s stem cell treatment costs about $1,800 for small animals, $2,400 for horses. Stem cells also can be frozen and banked for future use through MediVet Lab Services.

MEDIVET-AMERICA

A research and development company and global leader in veterinary stem cell technology, MediVet-America provides innovative cell applications for the therapeutic care of animals. Headquartered in Nicholasville, Kentucky, MediVet-America develops advanced cellular designed kits and services for the treatment of arthritis and degenerative joint disease. The company also offers MediVet Lab Services in multiple locations around the world that provides technical support for in-house stem cell vets, as well as regional and national Adipose stem cell processing and cryo banking services for pets at a young age or for a maintenance program, autologous conditioned serum processing, and cell counting for in-house stem cell procedures. http://www.MediVet-America.com

BUTLER SCHEIN ANIMAL HEALTH

Butler Schein Animal Health is the leading U.S. companion animal health distribution company. Headquartered in Dublin, Ohio, the company operates through 18 distribution centers and 12 telecenters. Approximately 900 Butler Schein Animal Health team members, including 300 field sales representatives and 200 telesales and customer support representatives, serve animal health customers in all 50 states. http://www.ButlerShein.com

###

Dick Roberts
Roberts Communications
(412) 535-5000
Email Information

Read more:
MediVet-America Partners With Butler Schein Animal Health to Distribute World's Leading Animal Stem Cell Technology to ...

Read More...

VistaGen Therapeutics Engages MissionIR as Its Investor Relations Advisor

February 23rd, 2012 2:24 am

ATLANTA, GA--(Marketwire -02/21/12)- VistaGen Therapeutics, Inc. (OTC.BB: VSTA.OB - News) (OTCQB: VSTA.OB - News), a biotechnology company applying stem cell technology for drug rescue and cell therapy, has retained MissionIR, a national investor relations consulting firm, to develop and implement a strategic investor relations campaign. Through a network of investor-oriented online websites and full suite of investor awareness services, MissionIR broadens the influence of publicly traded companies and enhances their ability to attract growth capital and improve shareholder value.

"VistaGen's work with human stem cell technology is groundbreaking," said Sherri Snyder, Director of Marketing at MissionIR. "The company's versatile platform, Human Clinical Trials in a Test Tube™, provides clinically relevant predictions of potential heart toxicity of new drug candidates long before they are ever tested on humans. Guided by a management team with decades of experience, VistaGen's stem cell technology can potentially save billions of dollars in the healthcare industry while recapturing prior R&D investment in once-promising new drug candidates."

"We are pleased to bring MissionIR on board as our external investor relations partner," said Shawn Singh, VistaGen's Chief Executive Officer. "The crucial work our company is doing can fundamentally change the way medicine is developed. Paired with MissionIR's global presence and sound investor relations programs, we can further grow our shareholder base and accelerate internal initiatives already in place to bring our stem cell technology platform to the forefront of drug development."

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. Through a full suite of investor relations and consultancy services, we help public companies develop and execute a strategic investor awareness plan as we've done for hundreds of others. Whether it's capital raising, increasing awareness among the financial community, or enhancing corporate communications, we offer a variety of solutions to meet the objectives of our clients.

For more information, visit http://www.MissionIR.com

About VistaGen Therapeutics

VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue and cell therapy. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern medicinal chemistry to generate new chemical variants of once-promising small-molecule drug candidates. These are once-promising drug candidates discontinued by pharmaceutical companies during development due to heart toxicity, despite positive efficacy data demonstrating their potential therapeutic and commercial benefits. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans.

Additionally, VistaGen's small molecule drug candidate, AV-101, is in Phase 1b development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S. alone. VistaGen plans to initiate Phase 2 clinical development of AV-101 in the fourth quarter of 2012. VistaGen is also exploring opportunities to leverage its current Phase 1 clinical program to enable additional Phase 2 clinical studies of AV-101 for epilepsy, Parkinson's disease and depression. To date, VistaGen has been awarded over $8.5 million from the NIH for development of AV-101.

Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen's Facebook page at http://www.facebook.com/VistaGen.

Read this article:
VistaGen Therapeutics Engages MissionIR as Its Investor Relations Advisor

Read More...

Pathfinder Presents Preliminary Data on New Regenerative Approach to Diabetes Treatment

February 23rd, 2012 2:24 am

CAMBRIDGE, Mass., Feb. 21, 2012 (GLOBE NEWSWIRE) -- Pathfinder Cell Therapy, Inc. ("Pathfinder," or "the Company") (OTCQB:PFND.PK - News), a biotechnology company focused on the treatment of diabetes and other diseases characterized by organ-specific cell damage, today presented preliminary data highlighting the potential of the Company's unique cell-based therapy for treating diabetes at the 7th Annual New York Stem Cell Summit. Richard L. Franklin, M.D., Ph.D., Founder, CEO and President of Pathfinder, provided an overview of the Company's Pathfinder Cell ("PC") technology, and presented preclinical evidence demonstrating how treatment with PCs was able to reverse the symptoms of diabetes in two different mouse models.

Pathfinder Cells are a newly identified non-stem cell mammalian cell type that has the ability to stimulate regeneration of damaged tissue without being incorporated into the new tissue. In today's presentation, Dr. Franklin showed how recent experiments performed using a non-obese diabetic (NOD) mouse strain were supportive of earlier data that demonstrated complete reversal of diabetes in mice. The earlier results, which used a drug-induced diabetic mouse model, were published in Rejuvenation Research1. Though preliminary, the recent results are encouraging because the NOD mouse model is widely used and highly regarded as being predictive of human type-1 diabetes.

In three separate experiments using this model, 30-50% of the mice treated with PCs at the onset of diabetes returned to normal blood glucose levels. Of the mice that responded well to treatment, the effects tended to be long lasting, up to two months in some cases after just two doses. These results, which were generated by intravenous injection of PC's derived from rat pancreatic tissue, further demonstrate the remarkable ability of Pathfinder Cells to elicit their positive effect regardless of the organ, or even species, of origin.

"We are very encouraged by these preclinical results using NOD mice. This model is the gold standard for type-1 diabetes and the fact that recent experiments mirror what we've seen in previous models may be highly significant," stated Dr. Franklin. "We have many questions to answer about how PCs act in the body, but we believe, based on previous experiments, that PCs may stimulate regeneration of damaged islet cells that produce insulin. The current NOD mouse data also suggest that PCs may have an effect in modulating the auto-immune process in type 1 diabetes. We continue to conduct experiments aimed at elucidating the optimal dosing and other factors that may be responsible for producing a robust and long-lasting response, as this will be critical as we start to think about how PCs may be used in treating human diabetes."

In his presentation today, Dr. Franklin also provided further insight into the mechanism of action of PCs, based on recent animal experiments. It was observed previously that PCs produce microvesicles, which are known to play a role in intercellular communication, but through mechanisms that are poorly understood. In a recent experiment, Pathfinder was able to isolate these microvesicles from the PCs and treat animals directly with an injection containing microvesicles only. Remarkably, both PC- and microvesicle-treated mice exhibited similar reductions in blood glucose compared to controls using the same drug-induced diabetes mouse model. This suggests, not only that the microvesicles produced by PCs are central to the mechanism of action, but that the microvesicles alone appear to be sufficient to produce the full effect.

Dr. Franklin commented, "If confirmed, this finding could have a significant positive impact on the future of PC-based therapy. Due to the relatively small amount of material contained within the microvesicles, determining the specific factor(s) that are responsible for regenerating damaged tissue could be more straightforward than we first anticipated, bringing us closer to understanding the mechanism of action. There may also be a number of potential manufacturing and storage benefits to using microvesicles versus PCs that will be interesting to explore in parallel as we work to advance this innovative new therapeutic approach closer to human clinical development."

The New York Stem Cell Summit brings together cell therapy company executives, researchers, investors and physicians to explore investment opportunities in cell therapy research and innovation. More information can be found at http://www.stemcellsummit.com.

Presentation details Event: 7th Annual New York Stem Cell Summit Date: Tuesday, February 21, 2012 Place: Bridgewaters New York, 11 Fulton Street, New York, NY Time: 3:35 pm ET

About Pathfinder

Pathfinder is developing a novel cell-based therapy and has generated encouraging preclinical data in models of diabetes, renal disease, myocardial infarction, and critical limb ischemia, a severe form of peripheral vascular disease. Leveraging its internal discovery of Pathfinder Cells ("PCs") Pathfinder is pioneering a new field in regenerative medicine.

PCs are a newly identified mammalian cell type present in very low quantities in a variety of organs, including the kidney, liver, pancreas, lymph nodes, myometrium, bone marrow and blood. Early studies indicate that PCs stimulate regeneration of damaged tissues without the cells themselves being incorporated into the newly generated tissue. Based on testing to date, the cells appear to be "immune privileged," and their effects appear to be independent of the tissue source of PCs. For more information please visit: http://www.pathfindercelltherapy.com.

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our inability to obtain additional required financing; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results, if any; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; technological changes; and government regulation. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

1Karen Stevenson, Daxin Chen, Alan MacIntyre, Liane M McGlynn, Paul Montague, Rawiya Charif, Murali Subramaniam, W.D. George, Anthony P. Payne, R. Wayne Davies, Anthony Dorling, and Paul G. Shiels. Rejuvenation Research. April 2011, 14(2): 163-171. doi:10.1089/rej.2010.1099

Read more:
Pathfinder Presents Preliminary Data on New Regenerative Approach to Diabetes Treatment

Read More...

Study: Stem Cells Reverse Heart Damage – Video

February 22nd, 2012 2:25 pm

15-02-2012 13:09 BY ALYSSA CARTEE ANCHOR MEGAN MURPHY A breakthrough discovery in stem cell treatments. A patient's own stem cells could actually regenerate the heart after a heart attack. WFLD explains the findings. "The studies found that recent heart attack victims who receive stem cell infusions had a drop in unhealthy heart scar tissue from 24 to 12 percent." The procedure is minimally invasive. A catheter is inserted through the patient's vein and a piece of heart muscle about the size of a peppercorn is removed. That biopsied tissue is then grown in a petri dish and reintroduced to the damaged portion of the heart. This new procedure could change the way heart attacks are treated. ABC reports the typical damage a heart attack leaves and the limited options for treatment. "The damaged scar tissue that results from a heart attack diminishes heart function, which can ultimately lead to enlargement of the heart. At best ... there are measures doctors can try to reduce or compensate for the damage, but in many cases, heart failure ultimately sets in, often requiring mechanical support or a transplant." But the new treatment challenges the conventional wisdom that once the heart is damaged, it can't be repaired. Doctor Sanjay Gupta told CNN this breakthrough in the use of stem cells means a few different things for the medical community. "We've been talking about the promise of stem cells for so long but people have really yet to see it in action. ... It really proved two things. First ...

View original post here:
Study: Stem Cells Reverse Heart Damage - Video

Read More...

Page 1,503«..1020..1,5021,5031,5041,505..1,5101,520..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick